Author:
Zarogoulidis P,Hohenforst-Schmidt W,Darwiche K,Krauss L,Sparopoulou D,Sakkas L,Gschwendtner A,Huang H,Turner F J,Freitag L,Zarogoulidis K
Publisher
Springer Science and Business Media LLC
Subject
Genetics,Molecular Biology,Molecular Medicine
Reference75 articles.
1. Liao BC, Lin CC, Yang JC . First-line management of egfr-mutated advanced lung adenocarcinoma: recent developments. Drugs 2013; 73: 357–369.
2. Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T . Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer 2011; 71: 249–257.
3. Li T, Kung HJ, Mack PC, Gandara DR . Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013; 31: 1039–1049.
4. Nelson V, Ziehr J, Agulnik M, Johnson M . Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther 2013; 6: 135–143.
5. Gadgeel SM, Wozniak A . Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin Lung Cancer 2013; S1525-7304: 00266-5.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献